New Long-Acting diabetes shot shows promise in first human test
NCT ID NCT06439056
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early study tested a single injection of NEX-22A, a long-acting version of the diabetes drug liraglutide, in 12 adults with type 2 diabetes. The main goal was to see how the drug moves through the body and if it is safe. Participants were on stable metformin therapy and received one dose. Results will help decide if further testing is warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NEX-22A (a long-acting form of liraglutide)
What this could lead to
If successful, this could lead to a once-weekly or less frequent injection for managing type 2 diabetes, improving convenience for patients.
What could go wrong
This is a very early Phase 1 study with only 12 participants, so it is too small to prove effectiveness or safety. The drug may not work as hoped or could cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Profil
Neuss, 41460, Germany